Search the Newsreel

Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position

Woodline Partners LP has reported an 8.1% beneficial ownership stake in Zevra Therapeutics, Inc. (ZVRA), amounting to 4,785,771 shares. This disclosure, made via an amended Schedule 13G, indicates that Woodline Partners has sole voting and dispositive power over these shares. The ownership percentage is …

Bernstein raises Tapestry stock price target to $185 on Coach growth

Bernstein SocGen Group has increased its price target for Tapestry Inc. (NYSE:TPR) to $185, citing the strong growth of its Coach brand. This adjustment comes amidst Tapestry's impressive financial performance, including 14% revenue growth and a 78% gross profit margin, with analysts noting the …

Candel Therapeutics (NASDAQ:CADL) Stock Price Down 4.6% After Earnings Miss

Candel Therapeutics (NASDAQ:CADL) stock fell 4.6% after reporting a quarterly loss of $0.52 per share, missing the consensus estimate of $0.27. Despite the earnings miss, management highlighted progress towards a biologics license application submission in Q4 and a first commercial product target for 2027. …

Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G/A, reporting a beneficial ownership of 3,436,000 shares of Voyager Therapeutics, Inc. (VYGR) common stock, which represents 5.58% of the class. They hold shared voting and dispositive power over these shares, which are directly …

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)

Vivos Therapeutics schedules Q2 2026 results, conference call

Vivos Therapeutics Inc (NASDAQ: VVOS) is set to release its second quarter 2026 financial results after market close on August 14, 2026. Following the release, the company will host a conference call at 5:00 pm ET to discuss the results, provide operational updates, and …

Why Medicenna Therapeutics Corp stock is skyrocketing today

OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210

This article provides detailed financial and analytical data for Ocular Therapeutix Inc (OCUL), including its live stock price, chart, news, and a comprehensive stock score. It covers key financial figures, performance over various periods, technical analysis, analyst ratings, and company profile. The data shows …

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen

Candel Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20.88, Implies 77% Upside

Candel Therapeutics, Inc. (CADL) has seen its average 12-month price target raised to $20.88 by analysts, up from $20.5, with individual forecasts ranging from $12 to $29. This new target suggests a potential upside of approximately 77% from its closing price on August 13. …

Tapestry (TPR) Is Down 20.7% After Soft 2027 Outlook Tempers Dividend Hike And Buybacks

Tapestry, Inc. has already reported fourth-quarter and full-year 2026 results, with sales rising to US$1,876.6 million and US$8,004.2 million respectively, alongside a swing from loss to profit and a Board-approved 16% increase in the quarterly dividend to US$0.4625 per share. The company also completed …

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G

T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 …

Galectin Therapeutics Releases Q2 2026 Financial Results

Galectin Therapeutics Inc. (GALT) reported a wider net loss of $0.14 per share, or $9.1 million, for Q2 2026, an increase from $0.12 per share in the prior year. This reflects the company's continued investment in developing new drugs for fibrotic disease and cancer …

T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1,472,984 shares in Atrium Therapeutics Inc., which constitutes an 8.6% stake in the company. The filing indicates that T. Rowe Price Associates holds sole voting power over 1,472,772 …

Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside

Eikon Therapeutics, Inc.'s average 12-month price target has been lowered to $24.6 from $24.8 by 5 analysts, with individual forecasts ranging from $4 to $32 per share. This new target suggests a potential upside of approximately 138% based on the August 13 closing price. …

Armistice Capital (DCOY) discloses 65,503-share, 9.99% holding in Decoy Therapeutics

Armistice Capital (BCYC) reports 3.40M Bicycle Therapeutics ADSs in 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 3,398,000 American Depositary Shares (ADSs) of Bicycle Therapeutics plc (BCYC). This represents 6.72% of the outstanding class as of June 30, 2026. All voting and dispositive power over …

DFTX News Today | Why did Definium Therapeutics stock go down today?

TPR Q4 Earnings Call Puts Coach Growth Durability in Focus

Tapestry, Inc. TPR used its fiscal fourth-quarter call to emphasize that Coach can sustain growth in fiscal 2027 despite a more measured second-half cadence. TPR reported adjusted earnings of $1.32 per share, which beat the Zacks Consensus Estimate of $1.26. Revenues of $1,876.6 million …

HC Wainwright Issues Negative Forecast for TARA Earnings

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

United Therapeutics's Q2 Earnings Call: Our Top 5 Analyst Questions United Therapeutics reported second quarter results that modestly exceeded Wall Street's revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized …

Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA)

HC Wainwright Has Positive Estimate for VERA Q3 Earnings

Allogene Therapeutics (ALLO) Income Statement & Earnings

Chenming Paper Faces RMB792.9 Million in New Litigation Amid Stable Operations

Filana Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | PX91 | US14817C1071

Werewolf Therapeutics Company Profile & Introduction

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)

Wedbush has reaffirmed an "Outperform" rating for Fate Therapeutics (NASDAQ:FATE), setting a target price of $7.00, which suggests a significant upside of approximately 178% from its current share price. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller-than-anticipated loss of $0.25 per share …

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 15,000,000 American Depositary Shares (ADSs) in Autolus Therapeutics plc (AUTL), representing 5.64% of the outstanding ADSs. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Tapestry Inc. (TPR) PT Raised to $185 at Bernstein SocGen Group

Bernstein SocGen Group analyst Aneesha Sherman has raised the price target for Tapestry Inc. (TPR) to $185. The article is a premium-only piece, requiring a subscription to StreetInsider.com for full access.

Why Is Capricor Therapeutics Stock Soaring Today? - Capricor Therapeutics (NASDAQ:CAPR)

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call

JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating

Oppenheimer has revised its price target for Abeona Therapeutics (ABEO) to $21 from $22, while reiterating an Outperform rating on the stock. This adjustment comes after Abeona Therapeutics' shares fell following a Q2 earnings miss. The article also provides a company profile, recent news, …